{
  "title": "Vaccine development needs new incentives (with Tahir Amin)",
  "description": "COVID-19 has exposed the limits of the pharmaceutical market model. This week, patent law expert Tahir Amin joins the show to explain why vaccine development needs new incentives.\n\nTahir Amin is an attorney dedicated to reshaping patent law to better serve the public. He is the Co-Founder and Co-ED of the Initiative for Medicines, Access, and Knowledge (I-MAK), a global nonprofit organization of attorneys, scientists, and health experts working on systemic changes to intellectual property and the political economy of pharmaceutical innovation. \n\nTwitter: @realtahiramin\n\nFurther reading: \nCovid-19 has exposed the limits of the pharmaceutical market model: https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/\n\nNo vaccine in sight: https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system\n\nDemocrats punt on drug-pricing overhaul in virus relief measure: https://news.bloomberglaw.com/health-law-and-business/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure\n\nWebsite: http://pitchforkeconomics.com/\nTwitter: @PitchforkEcon\nInstagram: @pitchforkeconomics\nNick’s twitter: @NickHanauer",
  "pubDate": "Tue, 16 Jun 2020 07:00:00 -0000",
  "itunes:episodeType": "full",
  "itunes:author": "Civic Ventures",
  "itunes:subtitle": "",
  "itunes:summary": "COVID-19 has exposed the limits of the pharmaceutical market model. This week, patent law expert Tahir Amin joins the show to explain why vaccine development needs new incentives.\n\nTahir Amin is an attorney dedicated to reshaping patent law to better serve the public. He is the Co-Founder and Co-ED of the Initiative for Medicines, Access, and Knowledge (I-MAK), a global nonprofit organization of attorneys, scientists, and health experts working on systemic changes to intellectual property and the political economy of pharmaceutical innovation. \n\nTwitter: @realtahiramin\n\nFurther reading: \nCovid-19 has exposed the limits of the pharmaceutical market model: https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/\n\nNo vaccine in sight: https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system\n\nDemocrats punt on drug-pricing overhaul in virus relief measure: https://news.bloomberglaw.com/health-law-and-business/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure\n\nWebsite: http://pitchforkeconomics.com/\nTwitter: @PitchforkEcon\nInstagram: @pitchforkeconomics\nNick’s twitter: @NickHanauer",
  "content:encoded": "<p>COVID-19 has exposed the limits of the pharmaceutical market model. This week, patent law expert Tahir Amin joins the show to explain why vaccine development needs new incentives.</p><p><br></p><p>Tahir Amin is an attorney dedicated to reshaping patent law to better serve the public. He is the Co-Founder and Co-ED of the Initiative for Medicines, Access, and Knowledge (I-MAK), a global nonprofit organization of attorneys, scientists, and health experts working on systemic changes to intellectual property and the political economy of pharmaceutical innovation. </p><p><br></p><p>Twitter: <a href=\"https://twitter.com/realtahiramin?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor\">@realtahiramin</a></p><p><br></p><p>Further reading: </p><p>Covid-19 has exposed the limits of the pharmaceutical market model: <a href=\"https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/\">https://www.statnews.com/2020/05/19/covid-19-exposed-limits-drug-development-model/</a></p><p><br></p><p>No vaccine in sight: <a href=\"https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system\">https://newrepublic.com/article/157594/no-coronavirus-vaccine-big-pharma-drug-patent-system</a></p><p><br></p><p>Democrats punt on drug-pricing overhaul in virus relief measure: <a href=\"https://news.bloomberglaw.com/health-law-and-business/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure\">https://news.bloomberglaw.com/health-law-and-business/democrats-punt-on-drug-pricing-overhaul-in-virus-relief-measure</a></p><p><br></p><p>Website: <a href=\"http://pitchforkeconomics.com/\">http://pitchforkeconomics.com/</a></p><p>Twitter: <a href=\"https://twitter.com/PitchforkEcon\">@PitchforkEcon</a></p><p>Instagram: <a href=\"https://www.instagram.com/pitchforkeconomics/?hl=en\">@pitchforkeconomics</a></p><p>Nick’s twitter: <a href=\"https://twitter.com/nickhanauer?lang=en\">@NickHanauer</a></p>",
  "itunes:duration": 1591,
  "guid": "5798813e-af69-11ea-ae21-57a6655e3d59",
  "enclosure": ""
}